Serum levels of angiogenic and anti-angiogenic factors: Their prognostic relevance in locally advanced hepatocellular carcinoma

Molecular and Cellular Biochemistry

Volumn 383, Issue 1-2, 2013, Pages 103-112

  Sharma, Bal Krishan ^a   Srinivasan, Radhika ^a   Kapil, Shweta ^a   Singla, Bhupesh ^a   Saini, Nitin ^a   Chawla, Yogesh Kumar ^a   Chakraborti, Anuradha ^a   Duseja, Ajay ^a   Kalra, Naveen ^a   Dhiman, Radha Krishan ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Ang 2; Angiostatin; Endostatin; Hepatocellular carcinoma; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOPOIETIN 2; ANGIOSTATIN; ENDOSTATIN; TUMOR MARKER; VASCULOTROPIN;

ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CHEMOEMBOLIZATION; CHRONIC HEPATITIS; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANGIOSTATINS; CARCINOMA, HEPATOCELLULAR; ENDOSTATINS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VESICULAR TRANSPORT PROTEINS;

EID: 84885418504     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1759-7     Document Type: Article

References (45)

1. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907-1917
2. Tanigawa N, Lu C, Mitsui T, Miura S (1997) Quantitation of sinusoid-like vessels in hepatocellular carcinoma: its clinical and prognostic significance. Hepatology 26:1216-1223
3. Ramanujan S, Koenig GC, Padera TP, Stoll BR, Jain RK (2000) Local imbalance of proangiogenic and antiangiogenic factors: a potential mechanism of focal necrosis and dormancy in tumors. Cancer Res 60:1442-1448
4. Westphal JR, Van't Hullenaar R, Peek R et al (2000) Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int J Cancer 86:768-776
5. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309
6. Asahara T, Chen D, Takahashi T et al (1998) Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 83:233-240
7. Hu TH, Huang CC, Wu CL et al (2005) Increased endostatin/collagen XVIII expression correlates with elevated VEGF level and poor prognosis in hepatocellular carcinoma. Mod Pathol 18:663-672
8. Schmidt A, Wenzel D, Thorey I, Werner S, Fleischmann BK, Bloch W (2005) Endostatin down-regulates soluble guanylate cyclase (sGC) in endothelial cells in vivo: influence of endostatin on vascular endothelial growth factor (VEGF) signaling. Endothelium 12:251-257
9. Zatterstrom UK, Felbor U, Fukai N, Olsen BR (2000) Collagen XVIII/endostatin structure and functional role in angiogenesis. Cell Struct Funct 25:97-101
10. O'Reilly MS, Boehm T, Shing Y et al (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285
11. O'Reilly MS, Holmgren L, Shing Y et al (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328
12. O'Reilly MS, Holmgren L, Chen C, Folkman J (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689-692
13. Lannutti BJ, Gately ST, Quevedo ME, Soff GA, Paller AS (1997) Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res 57:5277-5280
14. Wu Z, O'Reilly MS, Folkman J, Shing Y (1997) Suppression of tumor growth with recombinant murine angiostatin. Biochem Biophys Res Commun 236:651-654
15. Sim BK, O'Reilly MS, Liang H et al (1997) A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 57:1329-1334
16. Xie H, Song J, Liu K et al (2008) The expression of hypoxia-inducible factor-1alpha in hepatitis B virus-related hepatocellular carcinoma: correlation with patients' prognosis and hepatitis B virus X protein. Dig Dis Sci 53:3225-3233
17. Huang GW, Yang LY, Lu WQ (2005) Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival. World J Gastroenterol 11:1705-1708
18. Iavarone M, Lampertico P, Iannuzzi F et al (2007) Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. J Viral Hepat 14:133-139
19. Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST (2007) High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 14:1835-1845
20. Bruix J, Sherman M, Llovet JM et al (2001) EASL panel of experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421-430
21. Kaido T, Uemoto S (2008) Recent evidence in the treatment of small hepatocellular carcinoma. Hepatogastroenterology 55:1460-1462
22. Wada H, Nagano H, Yamamoto H et al (2006) Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma:importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int 26:414-423
23. Kim HS, Park JW, Jang JS et al (2009) Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. J Clin Gastroenterol 43:482-488
24. Sterling RK, Jeffers L, Gordon F et al (2009) Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol 7:104-113
25. Durazo FA, Blatt LM, Corey WG et al (2008) Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 23:1541-1548
26. Sharma B, Srinivasan R, Chawla YK et al (2010) Clinical utility of prothrombin induced by vitamin K absence in the detection of hepatocellular carcinoma in Indian population. Hepatol Int 4:569-576
27. el-Houseini ME, Mohammed MS, Elshemey WM, Hussein TD, Desouky OS, Elsayed AA (2005) Enhanced detection of hepatocellular carcinoma. Cancer Control 12:248-253
28. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X (2004) Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 10:2878-2882
29. Zhao J, Hu J, Cai J (2001) Significance of vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 23:389-392
30. Chao Y, Li CP, Chau GY et al (2003) Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 10:355-362
31. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST (2004) Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 91:1354-1360
32. Tamesa T, Iizuka N, Mori N et al (2009) High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma. Hepatogastroenterology 56:1122-1126
33. Niizeki T, Sumie S, Torimura T et al (2012) Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. J Gastroenterol 47:686-695
34. Poon RT, Lau C, Yu WC, Fan ST, Wong J (2004) High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep 11:1077-1084
35. Kaseb AO, Hassan MM, Lin E, et al. (2011) V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer 117:2478-2488
36. Dai CX, Gao Q, Qiu SJ et al (2009) Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer 9:418
37. Scholz A, Rehm VA, Rieke S et al (2007) Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma. Am J Gastroenterol 102:2471-2481
38. Uematsu S, Higashi T, Nouso K et al (2005) Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 20:583-588
39. Yamagata M, Shiratori Y, Dan Y et al (2000) Serum endostatin levels in patients with hepatocellular carcinoma. Ann Oncol 11:761-762
40. Dhar DK, Ono T, Yamanoi A et al (2002) Serum endostatin predicts tumor vascularity in hepatocellular carcinoma. Cancer 95:2188-2195
41. Lai R, Estey E, Shen Y et al (2002) Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome. Cancer 94:14-17
42. Rosmorduc O, Wendum D, Corpechot C et al (1999) Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am J Pathol 155:1065-1073
43. Drenberg CD, Saunders BO, Wilbanks GD et al (2010) Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer. Gynecol Oncol 117:117-124
44. Schmitz V, Raskopf E, Gonzalez-Carmona MA et al (2007) Plasminogen fragment K1-5 improves survival in a murine hepatocellular carcinoma model. Gut 56:271-278
45. Gorrin Rivas MJ, Arii S, Furutani M et al (1998) Expression of human macrophage metalloelastase gene in hepatocellular carcinoma: correlation with angiostatin generation and its clinical significance. Hepatology 28:986-993